Taysha Gene Therapies, Inc. (TSHA) CEO RA Session on Q2 2022 Results - Earnings Call Transcript

Aug. 13, 2022 11:25 AM ETTaysha Gene Therapies, Inc. (TSHA)
SA Transcripts profile picture
SA Transcripts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2022 Results Conference Call August 11, 2022 8:00 AM ET

Company Participants

Dr. Kimberly Lee - Chief Corporate Affairs Officer

RA Session - President, Founder, and Chief Executive Officer

Dr. Suyash Prasad - Chief Medical Officer and Head, R&D

Kamran Alam - Chief Financial Officer

Dr. Frederick Porter - Chief Technical Officer

Conference Call Participants

Joon Lee - Jo Securities

Gil Blum - Needham & Company

Mike Ulz - Morgan Stanley

Eun Yang - Jefferies

Jack Allen - Baird

Yun Zhong - BTIG

Sami Corwin - William Blair

Rick Miller - Cantor Fitzgerald


Greetings. Welcome to the Taysha Gene Therapies Second Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, August 11, 2022.

I'll now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Dr. Kimberly Lee

Good morning, and welcome to Taysha's Second Quarter 2022 Financial Results and Corporate Update Conference Call. Joining me on today's call are RA Session, II Taysha's President, Founder and CEO; Dr. Frederick Porter, Chief Technical Officer; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Kamran Alam, Chief Financial Officer.

After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time. Earlier today, Taysha issued a press release announcing financial results for the second quarter ending June 30, 2022. A copy of this press release is available on the company's website and through our SEC filings.

Please note that on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of our investigational

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.